IL296106A - הרכבים ושיטות לעיכוב ביטוי של טרנסתירטין (ttr) - Google Patents

Info

Publication number

IL296106A

IL296106A IL296106A IL29610622A IL296106A IL 296106 A IL296106 A IL 296106A IL 296106 A IL296106 A IL 296106A IL 29610622 A IL29610622 A IL 29610622A IL 296106 A IL296106 A IL 296106A

Authority

IL

Israel

Prior art keywords

ttr

rnai agent

fixed dose

double stranded

phosphate

Prior art date

2020-03-06

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims description 110
• 230000014509 gene expression Effects 0.000 title claims description 57
• 230000002401 inhibitory effect Effects 0.000 title claims description 13
• 108010071690 Prealbumin Proteins 0.000 title description 163
• 239000000203 mixture Substances 0.000 title description 12
• 102000009190 Transthyretin Human genes 0.000 title 1
• 239000003795 chemical substances by application Substances 0.000 claims description 227
• 102100029290 Transthyretin Human genes 0.000 claims description 201
• 230000009368 gene silencing by RNA Effects 0.000 claims description 196
• 125000003729 nucleotide group Chemical group 0.000 claims description 98
• 239000002773 nucleotide Substances 0.000 claims description 87
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 82
• 201000010099 disease Diseases 0.000 claims description 76
• 230000000692 anti-sense effect Effects 0.000 claims description 61
• 206010002022 amyloidosis Diseases 0.000 claims description 50
• 239000003446 ligand Substances 0.000 claims description 44
• 101000772194 Homo sapiens Transthyretin Proteins 0.000 claims description 43
• 108091081021 Sense strand Proteins 0.000 claims description 42
• 101150091380 TTR gene Proteins 0.000 claims description 41
• 230000008859 change Effects 0.000 claims description 38
• 108090000623 proteins and genes Proteins 0.000 claims description 33
• 108020004999 messenger RNA Proteins 0.000 claims description 31
• 102000004169 proteins and genes Human genes 0.000 claims description 29
• 102000039446 nucleic acids Human genes 0.000 claims description 24
• 108020004707 nucleic acids Proteins 0.000 claims description 24
• 201000001119 neuropathy Diseases 0.000 claims description 21
• 230000007823 neuropathy Effects 0.000 claims description 21
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 21
• -1 thymidine-glycol nucleic acid Chemical class 0.000 claims description 21
• OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 19
• 208000028389 Nerve injury Diseases 0.000 claims description 19
• 230000008764 nerve damage Effects 0.000 claims description 19
• 208000024891 symptom Diseases 0.000 claims description 19
• 230000006735 deficit Effects 0.000 claims description 18
• 229910052760 oxygen Inorganic materials 0.000 claims description 17
• 238000012360 testing method Methods 0.000 claims description 17
• 238000007920 subcutaneous administration Methods 0.000 claims description 14
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 12
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
• 208000022256 primary systemic amyloidosis Diseases 0.000 claims description 12
• 229910052717 sulfur Inorganic materials 0.000 claims description 12
• 230000009885 systemic effect Effects 0.000 claims description 11
• 208000012902 Nervous system disease Diseases 0.000 claims description 10
• 101000979333 Homo sapiens Neurofilament light polypeptide Proteins 0.000 claims description 8
• 102100023057 Neurofilament light polypeptide Human genes 0.000 claims description 8
• 206010036105 Polyneuropathy Diseases 0.000 claims description 8
• NPRNBAPBGVERRF-ZOQUXTDFSA-N [(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl] dihydrogen phosphate Chemical compound CO[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 NPRNBAPBGVERRF-ZOQUXTDFSA-N 0.000 claims description 8
• IATVSXSQCCSKNS-ZOQUXTDFSA-N [(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl] dihydrogen phosphate Chemical compound CO[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 IATVSXSQCCSKNS-ZOQUXTDFSA-N 0.000 claims description 8
• VXTNWQOOBHQEDS-IOSLPCCCSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl] dihydrogen phosphate Chemical compound CO[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VXTNWQOOBHQEDS-IOSLPCCCSA-N 0.000 claims description 8
• SQXGRYKQXLPVFG-AEHJODJJSA-N [(2r,3r,4s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@]1(O)F SQXGRYKQXLPVFG-AEHJODJJSA-N 0.000 claims description 8
• PTESHFKYBQMNFR-FJGDRVTGSA-N [(2r,3r,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 PTESHFKYBQMNFR-FJGDRVTGSA-N 0.000 claims description 8
• KLVQSNKMLGBSHV-GIWSHQQXSA-N [(2r,3r,4s,5r)-5-(6-aminopurin-9-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@]1(O)F KLVQSNKMLGBSHV-GIWSHQQXSA-N 0.000 claims description 8
• 230000007824 polyneuropathy Effects 0.000 claims description 8
• 206010007509 Cardiac amyloidosis Diseases 0.000 claims description 7
• QXWJIJPOAPZARX-KQYNXXCUSA-N [(2r,3r,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl] dihydrogen phosphate Chemical compound CO[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 QXWJIJPOAPZARX-KQYNXXCUSA-N 0.000 claims description 7
• 238000011161 development Methods 0.000 claims description 7
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 7
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 6
• 206010016202 Familial Amyloidosis Diseases 0.000 claims description 6
• 230000036541 health Effects 0.000 claims description 6
• 238000001990 intravenous administration Methods 0.000 claims description 6
• 230000001404 mediated effect Effects 0.000 claims description 6
• 102100023708 Coiled-coil domain-containing protein 80 Human genes 0.000 claims description 5
• 101000978383 Homo sapiens Coiled-coil domain-containing protein 80 Proteins 0.000 claims description 5
• 101000679907 Homo sapiens Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 claims description 5
• 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 claims description 5
• 239000002131 composite material Substances 0.000 claims description 5
• 239000003814 drug Substances 0.000 claims description 5
• 201000003968 hyperthyroxinemia Diseases 0.000 claims description 5
• 230000002861 ventricular Effects 0.000 claims description 5
• 206010064571 Gene mutation Diseases 0.000 claims description 4
• 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 claims description 4
• 102100022766 R-spondin-3 Human genes 0.000 claims description 4
• QGZHQRNBDZDKFW-FJGDRVTGSA-N [(2r,3r,4s,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound O[C@]1(F)[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 QGZHQRNBDZDKFW-FJGDRVTGSA-N 0.000 claims description 4
• 230000002567 autonomic effect Effects 0.000 claims description 4
• 230000000926 neurological effect Effects 0.000 claims description 4
• 229940071643 prefilled syringe Drugs 0.000 claims description 4
• 108090000751 Ceramidases Proteins 0.000 claims description 3
• 102100023996 Neutral ceramidase Human genes 0.000 claims description 3
• 229940090047 auto-injector Drugs 0.000 claims description 3
• 229940124597 therapeutic agent Drugs 0.000 claims description 3
• 208000027121 wild type ATTR amyloidosis Diseases 0.000 claims description 3
• 108091030071 RNAI Proteins 0.000 claims 32
• 210000003169 central nervous system Anatomy 0.000 claims 2
• 108010017384 Blood Proteins Proteins 0.000 claims 1
• 102000004506 Blood Proteins Human genes 0.000 claims 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
• 102400001263 NT-proBNP Human genes 0.000 claims 1
• 230000003862 health status Effects 0.000 claims 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
• 230000036470 plasma concentration Effects 0.000 claims 1
• 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 1
• 239000003381 stabilizer Substances 0.000 claims 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 164
• 238000011282 treatment Methods 0.000 description 70
• 125000005647 linker group Chemical group 0.000 description 68
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 63
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 45
• 210000004027 cell Anatomy 0.000 description 42
• 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 37
• 201000007905 transthyretin amyloidosis Diseases 0.000 description 36
• 230000007423 decrease Effects 0.000 description 32
• 230000004048 modification Effects 0.000 description 27
• 238000012986 modification Methods 0.000 description 27
• 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 25
• 230000035772 mutation Effects 0.000 description 24
• 235000000346 sugar Nutrition 0.000 description 23
• 238000003776 cleavage reaction Methods 0.000 description 22
• 230000007017 scission Effects 0.000 description 22
• 210000002966 serum Anatomy 0.000 description 22
• 150000001875 compounds Chemical class 0.000 description 21
• 239000000090 biomarker Substances 0.000 description 20
• 230000000295 complement effect Effects 0.000 description 20
• 230000000747 cardiac effect Effects 0.000 description 19
• 210000003205 muscle Anatomy 0.000 description 19
• 230000005764 inhibitory process Effects 0.000 description 18
• 239000002253 acid Substances 0.000 description 17
• 210000004369 blood Anatomy 0.000 description 17
• 239000008280 blood Substances 0.000 description 17
• 230000006872 improvement Effects 0.000 description 17
• 230000003247 decreasing effect Effects 0.000 description 15
• 239000000902 placebo Substances 0.000 description 15
• 229940068196 placebo Drugs 0.000 description 15
• 239000008194 pharmaceutical composition Substances 0.000 description 14
• 230000009467 reduction Effects 0.000 description 14
• 108091034117 Oligonucleotide Proteins 0.000 description 13
• 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 12
• 235000014633 carbohydrates Nutrition 0.000 description 12
• 150000007523 nucleic acids Chemical class 0.000 description 12
• 206010061818 Disease progression Diseases 0.000 description 11
• 150000001720 carbohydrates Chemical class 0.000 description 11
• 230000005750 disease progression Effects 0.000 description 11
• 230000003278 mimic effect Effects 0.000 description 11
• 108090000765 processed proteins & peptides Proteins 0.000 description 11
• 230000011514 reflex Effects 0.000 description 11
• 208000037259 Amyloid Plaque Diseases 0.000 description 10
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 10
• 230000000977 initiatory effect Effects 0.000 description 10
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 10
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 9
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 9
• 125000004429 atom Chemical group 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 229910052799 carbon Inorganic materials 0.000 description 9
• 230000000694 effects Effects 0.000 description 9
• 150000002148 esters Chemical class 0.000 description 9
• 239000002777 nucleoside Substances 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 210000003414 extremity Anatomy 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 210000004185 liver Anatomy 0.000 description 8
• 230000033001 locomotion Effects 0.000 description 8
• 239000000178 monomer Substances 0.000 description 8
• 239000000523 sample Substances 0.000 description 8
• 206010002023 Amyloidoses Diseases 0.000 description 7
• 229910019142 PO4 Inorganic materials 0.000 description 7
• 108020004459 Small interfering RNA Proteins 0.000 description 7
• 125000000217 alkyl group Chemical group 0.000 description 7
• 230000003941 amyloidogenesis Effects 0.000 description 7
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
• 210000005036 nerve Anatomy 0.000 description 7
• 230000007830 nerve conduction Effects 0.000 description 7
• 210000000056 organ Anatomy 0.000 description 7
• 229950005564 patisiran Drugs 0.000 description 7
• 239000010452 phosphate Substances 0.000 description 7
• 230000035807 sensation Effects 0.000 description 7
• 230000001953 sensory effect Effects 0.000 description 7
• BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 7
• 230000008685 targeting Effects 0.000 description 7
• 229940034208 thyroxine Drugs 0.000 description 7
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 7
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
• 102000035195 Peptidases Human genes 0.000 description 6
• 108091005804 Peptidases Proteins 0.000 description 6
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 6
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 6
• 208000034700 Vitreous opacities Diseases 0.000 description 6
• 229940024606 amino acid Drugs 0.000 description 6
• 150000001413 amino acids Chemical class 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
• 208000035475 disorder Diseases 0.000 description 6
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 6
• 102000029752 retinol binding Human genes 0.000 description 6
• 108091000053 retinol binding Proteins 0.000 description 6
• 239000004576 sand Substances 0.000 description 6
• 102000009091 Amyloidogenic Proteins Human genes 0.000 description 5
• 108010048112 Amyloidogenic Proteins Proteins 0.000 description 5
• 108090000371 Esterases Proteins 0.000 description 5
• 230000002378 acidificating effect Effects 0.000 description 5
• 150000001408 amides Chemical group 0.000 description 5
• 230000003942 amyloidogenic effect Effects 0.000 description 5
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
• 229940104302 cytosine Drugs 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Natural products CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 5
• 102000056556 human TTR Human genes 0.000 description 5
• 238000009396 hybridization Methods 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 239000001301 oxygen Substances 0.000 description 5
• 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 5
• 230000000630 rising effect Effects 0.000 description 5
• 102200150628 rs151220873 Human genes 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• QPHRQMAYYMYWFW-FJGDRVTGSA-N 1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 QPHRQMAYYMYWFW-FJGDRVTGSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 206010019280 Heart failures Diseases 0.000 description 4
• 102100020870 La-related protein 6 Human genes 0.000 description 4
• 108050008265 La-related protein 6 Proteins 0.000 description 4
• 208000002193 Pain Diseases 0.000 description 4
• 241000282320 Panthera leo Species 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• 206010040030 Sensory loss Diseases 0.000 description 4
• 241000384008 Sisis Species 0.000 description 4
• 230000036982 action potential Effects 0.000 description 4
• 125000000304 alkynyl group Chemical group 0.000 description 4
• 125000003118 aryl group Chemical group 0.000 description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 230000004064 dysfunction Effects 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 208000017169 kidney disease Diseases 0.000 description 4
• 150000002632 lipids Chemical group 0.000 description 4
• 210000003141 lower extremity Anatomy 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 230000008035 nerve activity Effects 0.000 description 4
• 150000003833 nucleoside derivatives Chemical class 0.000 description 4
• 125000003835 nucleoside group Chemical group 0.000 description 4
• 210000004345 peroneal nerve Anatomy 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
• 125000004437 phosphorous atom Chemical group 0.000 description 4
• 229910052698 phosphorus Inorganic materials 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
• 102000001049 Amyloid Human genes 0.000 description 3
• 108010094108 Amyloid Proteins 0.000 description 3
• 206010010904 Convulsion Diseases 0.000 description 3
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
• 206010012289 Dementia Diseases 0.000 description 3
• 238000012286 ELISA Assay Methods 0.000 description 3
• 206010028570 Myelopathy Diseases 0.000 description 3
• 108091093037 Peptide nucleic acid Proteins 0.000 description 3
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 208000007107 Stomach Ulcer Diseases 0.000 description 3
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 125000002947 alkylene group Chemical group 0.000 description 3
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 125000002619 bicyclic group Chemical group 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 235000012000 cholesterol Nutrition 0.000 description 3
• 230000003413 degradative effect Effects 0.000 description 3
• 230000008021 deposition Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 238000002405 diagnostic procedure Methods 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 230000003467 diminishing effect Effects 0.000 description 3
• 210000001163 endosome Anatomy 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 201000005917 gastric ulcer Diseases 0.000 description 3
• 230000007160 gastrointestinal dysfunction Effects 0.000 description 3
• 230000030279 gene silencing Effects 0.000 description 3
• 230000005484 gravity Effects 0.000 description 3
• 230000004217 heart function Effects 0.000 description 3
• 229910052739 hydrogen Inorganic materials 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• 210000005229 liver cell Anatomy 0.000 description 3
• 150000002772 monosaccharides Chemical group 0.000 description 3
• 210000000653 nervous system Anatomy 0.000 description 3
• 208000035824 paresthesia Diseases 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 210000002381 plasma Anatomy 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 235000019833 protease Nutrition 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000029058 respiratory gaseous exchange Effects 0.000 description 3
• 229960003471 retinol Drugs 0.000 description 3
• 235000020944 retinol Nutrition 0.000 description 3
• 239000011607 retinol Substances 0.000 description 3
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 3
• 238000010254 subcutaneous injection Methods 0.000 description 3
• 239000007929 subcutaneous injection Substances 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 230000008719 thickening Effects 0.000 description 3
• 210000002303 tibia Anatomy 0.000 description 3
• 238000011830 transgenic mouse model Methods 0.000 description 3
• 235000019155 vitamin A Nutrition 0.000 description 3
• 239000011719 vitamin A Substances 0.000 description 3
• 229940045997 vitamin a Drugs 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
• HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 229930024421 Adenine Natural products 0.000 description 2
• IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
• 229940122361 Bisphosphonate Drugs 0.000 description 2
• 206010010774 Constipation Diseases 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
• 208000010228 Erectile Dysfunction Diseases 0.000 description 2
• 208000010412 Glaucoma Diseases 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 208000004044 Hypesthesia Diseases 0.000 description 2
• 208000001953 Hypotension Diseases 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 2
• 101100154773 Macaca fascicularis TTR gene Proteins 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 101100154776 Mus musculus Ttr gene Proteins 0.000 description 2
• OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 206010033799 Paralysis Diseases 0.000 description 2
• 206010034568 Peripheral coldness Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 229910020008 S(O) Inorganic materials 0.000 description 2
• 241000527181 Sisor Species 0.000 description 2
• 206010043248 Tendon rupture Diseases 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
• 241000335654 Uracis Species 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 230000003187 abdominal effect Effects 0.000 description 2
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 125000003368 amide group Chemical group 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
• 206010003119 arrhythmia Diseases 0.000 description 2
• 125000005018 aryl alkenyl group Chemical group 0.000 description 2
• 125000003710 aryl alkyl group Chemical group 0.000 description 2
• 230000001174 ascending effect Effects 0.000 description 2
• 150000004663 bisphosphonates Chemical class 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 230000000875 corresponding effect Effects 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 125000000753 cycloalkyl group Chemical group 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
• 229960000616 diflunisal Drugs 0.000 description 2
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 238000002592 echocardiography Methods 0.000 description 2
• 238000002565 electrocardiography Methods 0.000 description 2
• 210000002683 foot Anatomy 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 229930182830 galactose Natural products 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 125000001475 halogen functional group Chemical group 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
• 208000034783 hypoesthesia Diseases 0.000 description 2
• 230000036543 hypotension Effects 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 201000001881 impotence Diseases 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 210000003712 lysosome Anatomy 0.000 description 2
• 230000001868 lysosomic effect Effects 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 230000003340 mental effect Effects 0.000 description 2
• 230000004630 mental health Effects 0.000 description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
• 230000001144 postural effect Effects 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• 210000001747 pupil Anatomy 0.000 description 2
• 210000001525 retina Anatomy 0.000 description 2
• 229920002477 rna polymer Polymers 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 125000004434 sulfur atom Chemical group 0.000 description 2
• RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• TXEIIPDJKFWEEC-UHFFFAOYSA-N tafamidis Chemical compound O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 TXEIIPDJKFWEEC-UHFFFAOYSA-N 0.000 description 2
• 229960001353 tafamidis Drugs 0.000 description 2
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
• 229940113082 thymine Drugs 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
• 210000000623 ulna Anatomy 0.000 description 2
• 229940035893 uracil Drugs 0.000 description 2
• PMBSJRVVKHNWGX-GIWSHQQXSA-N (2r,3s,4r,5r)-2-(6-aminopurin-9-yl)-4-dihydroxyphosphinothioyloxy-3-fluoro-5-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=S)[C@]1(O)F PMBSJRVVKHNWGX-GIWSHQQXSA-N 0.000 description 1
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
• BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
• QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
• 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
• 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
• FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
• KLEGMTRDCCDFJK-XDQSQZFTSA-N 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[hydroxy-[(2R,3R,4R,5R)-2-(hydroxymethyl)-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound COCCO[C@@H]1[C@H](O)[C@@H](COP(O)(=S)O[C@@H]2[C@@H](COP(O)(=S)O[C@@H]3[C@@H](COP(O)(=S)O[C@@H]4[C@@H](COP(O)(=S)O[C@@H]5[C@@H](COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@@H]6[C@@H](COP(O)(=S)O[C@@H]7[C@@H](COP(O)(=S)O[C@@H]8[C@@H](COP(S)(=O)O[C@@H]9[C@@H](COP(O)(=S)O[C@@H]%10[C@@H](CO)O[C@H]([C@@H]%10OCCOC)n%10cc(C)c(=O)[nH]c%10=O)O[C@H]([C@@H]9OCCOC)n9cc(C)c(N)nc9=O)O[C@H]([C@@H]8OCCOC)n8cc(C)c(=O)[nH]c8=O)O[C@H]([C@@H]7OCCOC)n7cc(C)c(=O)[nH]c7=O)O[C@H]([C@@H]6OCCOC)n6cnc7c6nc(N)[nH]c7=O)n6cnc7c6nc(N)[nH]c7=O)n6cc(C)c(=O)[nH]c6=O)n6cc(C)c(=O)[nH]c6=O)n6cnc7c(N)ncnc67)n6cc(C)c(N)nc6=O)n6cnc7c(N)ncnc67)n6cc(C)c(=O)[nH]c6=O)n6cnc7c6nc(N)[nH]c7=O)n6cnc7c(N)ncnc67)n6cnc7c(N)ncnc67)O[C@H]([C@@H]5OCCOC)n5cnc6c(N)ncnc56)O[C@H]([C@@H]4OCCOC)n4cc(C)c(=O)[nH]c4=O)O[C@H]([C@@H]3OCCOC)n3cc(C)c(N)nc3=O)O[C@H]([C@@H]2OCCOC)n2cc(C)c(N)nc2=O)O[C@H]1n1cc(C)c(N)nc1=O KLEGMTRDCCDFJK-XDQSQZFTSA-N 0.000 description 1
• UIFJBEWVRSHKCF-ZOQUXTDFSA-N 1-[(2r,3r,4r,5r)-4-dihydroxyphosphinothioyloxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]pyrimidine-2,4-dione Chemical compound CO[C@@H]1[C@H](OP(O)(O)=S)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 UIFJBEWVRSHKCF-ZOQUXTDFSA-N 0.000 description 1
• QXMLYBQBMGZPTE-LTNPLRIYSA-N 1-[(2r,3s,4r,5r)-4-dihydroxyphosphinothioyloxy-3-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@](F)(O)[C@H](OP(O)(O)=S)[C@@H](CO)O1 QXMLYBQBMGZPTE-LTNPLRIYSA-N 0.000 description 1
• XKKRMVGRQHZUHY-FJGDRVTGSA-N 1-[(2r,3s,4r,5r)-4-dihydroxyphosphinothioyloxy-3-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@]1(F)[C@H](OP(O)(O)=S)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 XKKRMVGRQHZUHY-FJGDRVTGSA-N 0.000 description 1
• UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
• IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
• PXSCCKWNFZTKMS-UHFFFAOYSA-N 2-(2-aminopropyl)-7H-purin-6-amine 5-prop-1-ynyl-1H-pyrimidine-2,4-dione Chemical compound C(#CC)C=1C(NC(NC1)=O)=O.NC(CC1=NC(=C2NC=NC2=N1)N)C PXSCCKWNFZTKMS-UHFFFAOYSA-N 0.000 description 1
• PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
• BVQKNSCKIBSOGA-KQYNXXCUSA-N 2-amino-9-[(2r,3r,4r,5r)-4-dihydroxyphosphinothioyloxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-3h-purin-6-one Chemical compound CO[C@@H]1[C@H](OP(O)(O)=S)[C@@H](CO)O[C@H]1N1C(NC(N)=NC2=O)=C2N=C1 BVQKNSCKIBSOGA-KQYNXXCUSA-N 0.000 description 1
• QFOCLINPINTVJI-UUOKFMHZSA-N 2-amino-9-[(2r,3r,4s,5r)-4-dihydroxyphosphinothioyloxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=S)[C@H]1O QFOCLINPINTVJI-UUOKFMHZSA-N 0.000 description 1
• PLWXKAOZQSMLOO-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-4-dihydroxyphosphinothioyloxy-3-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=S)[C@]1(O)F PLWXKAOZQSMLOO-AEHJODJJSA-N 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• UOOOPKANIPLQPU-XVFCMESISA-N 3'-CMP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 UOOOPKANIPLQPU-XVFCMESISA-N 0.000 description 1
• FOGRQMPFHUHIGU-XVFCMESISA-N 3'-UMP Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-XVFCMESISA-N 0.000 description 1
• ZCFXTYHOHYXCTE-FJGDRVTGSA-N 4-amino-1-[(2r,3s,4r,5r)-4-dihydroxyphosphinothioyloxy-3-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](OP(O)(O)=S)[C@@H](CO)O1 ZCFXTYHOHYXCTE-FJGDRVTGSA-N 0.000 description 1
• ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• VPIAFVALSSSQJN-RGURZIINSA-N 6-amino-1-[(2s)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]hexan-1-one Chemical compound NCCCCCC(=O)N1CC(O)C[C@H]1CO VPIAFVALSSSQJN-RGURZIINSA-N 0.000 description 1
• DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
• QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
• LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
• HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
• LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
• 229960005508 8-azaguanine Drugs 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 108090000531 Amidohydrolases Proteins 0.000 description 1
• 102000004092 Amidohydrolases Human genes 0.000 description 1
• 241000554155 Andes Species 0.000 description 1
• 102100034608 Angiopoietin-2 Human genes 0.000 description 1
• 102000007592 Apolipoproteins Human genes 0.000 description 1
• 108010071619 Apolipoproteins Proteins 0.000 description 1
• 206010061666 Autonomic neuropathy Diseases 0.000 description 1
• 102100031500 Beta-1,4-glucuronyltransferase 1 Human genes 0.000 description 1
• 102100026031 Beta-glucuronidase Human genes 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
• 102100027207 CD27 antigen Human genes 0.000 description 1
• 102100029380 CMRF35-like molecule 2 Human genes 0.000 description 1
• 101100241173 Caenorhabditis elegans dat-1 gene Proteins 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102100032219 Cathepsin D Human genes 0.000 description 1
• GXCRUTWHNMMJEK-WYUVZMMLSA-M Cefacetrile sodium Chemical compound [Na+].S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 GXCRUTWHNMMJEK-WYUVZMMLSA-M 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 239000004380 Cholic acid Substances 0.000 description 1
• 102100021864 Cocaine esterase Human genes 0.000 description 1
• 241000518994 Conta Species 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• UOOOPKANIPLQPU-UHFFFAOYSA-N Cytidylic acid B Natural products O=C1N=C(N)C=CN1C1C(O)C(OP(O)(O)=O)C(CO)O1 UOOOPKANIPLQPU-UHFFFAOYSA-N 0.000 description 1
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 102100026662 Delta and Notch-like epidermal growth factor-related receptor Human genes 0.000 description 1
• 102100037986 Dickkopf-related protein 4 Human genes 0.000 description 1
• 101710099554 Dickkopf-related protein 4 Proteins 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 102100040502 Draxin Human genes 0.000 description 1
• 101150086587 Draxin gene Proteins 0.000 description 1
• 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 208000027534 Emotional disease Diseases 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 241000736355 Euthyroides Species 0.000 description 1
• 102100023590 Fibroblast growth factor-binding protein 1 Human genes 0.000 description 1
• 101710094971 Fibroblast growth factor-binding protein 1 Proteins 0.000 description 1
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 102100034190 Glypican-1 Human genes 0.000 description 1
• 101150085568 HSPB6 gene Proteins 0.000 description 1
• 102100039170 Heat shock protein beta-6 Human genes 0.000 description 1
• 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
• 101000729794 Homo sapiens Beta-1,4-glucuronyltransferase 1 Proteins 0.000 description 1
• 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 1
• 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
• 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
• 101000990046 Homo sapiens CMRF35-like molecule 2 Proteins 0.000 description 1
• 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
• 101000898006 Homo sapiens Cocaine esterase Proteins 0.000 description 1
• 101001054266 Homo sapiens Delta and Notch-like epidermal growth factor-related receptor Proteins 0.000 description 1
• 101001070736 Homo sapiens Glypican-1 Proteins 0.000 description 1
• 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
• 101001051272 Homo sapiens Layilin Proteins 0.000 description 1
• 101000938676 Homo sapiens Liver carboxylesterase 1 Proteins 0.000 description 1
• 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
• 101000585663 Homo sapiens Myocilin Proteins 0.000 description 1
• 101000617708 Homo sapiens Pregnancy-specific beta-1-glycoprotein 1 Proteins 0.000 description 1
• 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
• 101000650117 Homo sapiens Protein Wnt-9a Proteins 0.000 description 1
• 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 description 1
• 101000651309 Homo sapiens Retinoic acid receptor responder protein 1 Proteins 0.000 description 1
• 101000617796 Homo sapiens SPARC-related modular calcium-binding protein 1 Proteins 0.000 description 1
• 101000708790 Homo sapiens SPARC-related modular calcium-binding protein 2 Proteins 0.000 description 1
• 101000785978 Homo sapiens Sphingomyelin phosphodiesterase Proteins 0.000 description 1
• 101000642262 Homo sapiens Spondin-1 Proteins 0.000 description 1
• 101000669511 Homo sapiens T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 description 1
• 101000893741 Homo sapiens Tissue alpha-L-fucosidase Proteins 0.000 description 1
• 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
• 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 1
• 101000617921 Homo sapiens VPS10 domain-containing receptor SorCS2 Proteins 0.000 description 1
• 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 206010022061 Injection site erythema Diseases 0.000 description 1
• 206010022086 Injection site pain Diseases 0.000 description 1
• 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
• 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
• 102100039340 Interleukin-18 receptor 1 Human genes 0.000 description 1
• 101710184759 Interleukin-18 receptor 1 Proteins 0.000 description 1
• 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 1
• 101710169536 Interleukin-4 receptor subunit alpha Proteins 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• 102100034872 Kallikrein-4 Human genes 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
• 102100039648 Lactadherin Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102100024621 Layilin Human genes 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
• 102100020983 Lysosome membrane protein 2 Human genes 0.000 description 1
• 101000845005 Macrovipera lebetina Disintegrin lebein-2-alpha Proteins 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 241000283956 Manis Species 0.000 description 1
• 101710151321 Melanostatin Proteins 0.000 description 1
• 241001068914 Melicope knudsenii Species 0.000 description 1
• LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
• 102000015728 Mucins Human genes 0.000 description 1
• 108010063954 Mucins Proteins 0.000 description 1
• 208000001089 Multiple system atrophy Diseases 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 102100029839 Myocilin Human genes 0.000 description 1
• 102100036836 Natriuretic peptides B Human genes 0.000 description 1
• 101710187802 Natriuretic peptides B Proteins 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 102400000064 Neuropeptide Y Human genes 0.000 description 1
• 241001316086 Novocrania Species 0.000 description 1
• 229910004679 ONO2 Inorganic materials 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 241000083552 Oligomeris Species 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 206010031127 Orthostatic hypotension Diseases 0.000 description 1
• 239000007990 PIPES buffer Substances 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
• 102100027503 Protein Wnt-9a Human genes 0.000 description 1
• 101710150593 Protein beta Proteins 0.000 description 1
• 108010026552 Proteome Proteins 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 235000013929 Psidium pyriferum Nutrition 0.000 description 1
• 244000236580 Psidium pyriferum Species 0.000 description 1
• 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 1
• 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 102100022762 R-spondin-1 Human genes 0.000 description 1
• 101000633881 Rattus norvegicus Transthyretin Proteins 0.000 description 1
• 101100208299 Rattus norvegicus Ttr gene Proteins 0.000 description 1
• 102100027682 Retinoic acid receptor responder protein 1 Human genes 0.000 description 1
• 108091005488 SCARB2 Proteins 0.000 description 1
• 102100021995 SPARC-related modular calcium-binding protein 1 Human genes 0.000 description 1
• 102100032724 SPARC-related modular calcium-binding protein 2 Human genes 0.000 description 1
• 235000015076 Shorea robusta Nutrition 0.000 description 1
• 244000166071 Shorea robusta Species 0.000 description 1
• 208000010261 Small Fiber Neuropathy Diseases 0.000 description 1
• 206010073928 Small fibre neuropathy Diseases 0.000 description 1
• 102100026263 Sphingomyelin phosphodiesterase Human genes 0.000 description 1
• 102100036428 Spondin-1 Human genes 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
• 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 description 1
• 101150057833 THEG gene Proteins 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 102000011923 Thyrotropin Human genes 0.000 description 1
• 108010061174 Thyrotropin Proteins 0.000 description 1
• 102100040526 Tissue alpha-L-fucosidase Human genes 0.000 description 1
• 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
• 108091032917 Transfer-messenger RNA Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 108050000089 Transthyretin Proteins 0.000 description 1
• 102000014456 Trefoil Factor-3 Human genes 0.000 description 1
• 108010078184 Trefoil Factor-3 Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 1
• FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 description 1
• 102100021938 VPS10 domain-containing receptor SorCS2 Human genes 0.000 description 1
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
• 229930003779 Vitamin B12 Natural products 0.000 description 1
• 102000021095 WAP Four-Disulfide Core Domain Protein 2 Human genes 0.000 description 1
• 108091002660 WAP Four-Disulfide Core Domain Protein 2 Proteins 0.000 description 1
• 239000005862 Whey Substances 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• 102000007544 Whey Proteins Human genes 0.000 description 1
• VZKAGFPIGOSWMA-IOSLPCCCSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-dihydroxyphosphinothioyloxy-4-methoxyoxolan-2-yl]methanol Chemical compound CO[C@@H]1[C@H](OP(O)(O)=S)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VZKAGFPIGOSWMA-IOSLPCCCSA-N 0.000 description 1
• DUDZRBVSHCOKLU-LTNPLRIYSA-N [(2r,3r,4s,5r)-4-fluoro-4-hydroxy-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl] dihydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@](F)(O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 DUDZRBVSHCOKLU-LTNPLRIYSA-N 0.000 description 1
• XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 125000005217 alkenylheteroaryl group Chemical group 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
• 125000004419 alkynylene group Chemical group 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 125000005015 aryl alkynyl group Chemical group 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 230000001746 atrial effect Effects 0.000 description 1
• 230000037424 autonomic function Effects 0.000 description 1
• 230000009910 autonomic response Effects 0.000 description 1
• 230000037429 base substitution Effects 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
• 229960002471 cholic acid Drugs 0.000 description 1
• 235000019416 cholic acid Nutrition 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 210000003792 cranial nerve Anatomy 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• ZDPUTNZENXVHJC-UHFFFAOYSA-N cumingianoside D Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(OP(O)(O)=O)C1O ZDPUTNZENXVHJC-UHFFFAOYSA-N 0.000 description 1
• 108010032220 cyclomaltodextrinase Proteins 0.000 description 1
• KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 125000003843 furanosyl group Chemical group 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• ZDPUTNZENXVHJC-UUOKFMHZSA-N guanosine 3'-monophosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O ZDPUTNZENXVHJC-UUOKFMHZSA-N 0.000 description 1
• 210000001255 hallux Anatomy 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 125000001072 heteroaryl group Chemical group 0.000 description 1
• 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
• 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 150000002431 hydrogen Chemical group 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000001427 incoherent neutron scattering Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229950002218 inotersen Drugs 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 108010024383 kallikrein 4 Proteins 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 206010025005 lumbar spinal stenosis Diseases 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• QVRVXSZKCXFBTE-UHFFFAOYSA-N n-[4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)butyl]-2-(2-fluoroethoxy)-5-methylbenzamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCNC(=O)C1=CC(C)=CC=C1OCCF QVRVXSZKCXFBTE-UHFFFAOYSA-N 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000007658 neurological function Effects 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 1
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
• 235000003715 nutritional status Nutrition 0.000 description 1
• 230000009437 off-target effect Effects 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 108010064470 polyaspartate Proteins 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000017692 primary erythermalgia Diseases 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 230000009430 psychological distress Effects 0.000 description 1
• 230000010490 psychological well-being Effects 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 230000001698 pyrogenic effect Effects 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 239000002265 redox agent Substances 0.000 description 1
• 239000013074 reference sample Substances 0.000 description 1
• 125000006853 reporter group Chemical group 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 238000013077 scoring method Methods 0.000 description 1
• 210000004911 serous fluid Anatomy 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• QPILZZVXGUNELN-UHFFFAOYSA-M sodium;4-amino-5-hydroxynaphthalene-2,7-disulfonate;hydron Chemical compound [Na+].OS(=O)(=O)C1=CC(O)=C2C(N)=CC(S([O-])(=O)=O)=CC2=C1 QPILZZVXGUNELN-UHFFFAOYSA-M 0.000 description 1
• 238000010532 solid phase synthesis reaction Methods 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 208000005198 spinal stenosis Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 150000003457 sulfones Chemical group 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 210000001590 sural nerve Anatomy 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 210000002437 synoviocyte Anatomy 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• DQJDBUPLRMRBAB-WZTVWXICSA-N tafamidis meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 DQJDBUPLRMRBAB-WZTVWXICSA-N 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 150000003568 thioethers Chemical class 0.000 description 1
• 229960000874 thyrotropin Drugs 0.000 description 1
• 230000001748 thyrotropin Effects 0.000 description 1
• 210000002972 tibial nerve Anatomy 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 150000004043 trisaccharides Chemical class 0.000 description 1
• 210000000658 ulnar nerve Anatomy 0.000 description 1
• 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 235000019163 vitamin B12 Nutrition 0.000 description 1
• 239000011715 vitamin B12 Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1